Physician profile
Michael Sherman
NPI 1972822773
$9,486.98
in general payments reported to CMS, 2019-2025
35 companies · $1,176 in 2025
The $1,176 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $157 · 2021: $1,014 · 2022: $3,316 · 2023: $2,675 · 2024: $974 · 2025: $1,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,825.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,002.30 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,081.36 | 2019-2024 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $922.25 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Qol Medical, LLC | $665.03 | 2021-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $658.66 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Genzyme Corporation | $648.40 | 2022-2025 | |
| Pfizer INC. | $605.88 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $439.07 | 2022-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $381.80 | 2022-2025 | Ocaliva |
| Redhill Biopharma INC. | $303.48 | 2021-2023 | Movantik, Talicia, Aemcolo |
| Celgene Corporation | $165.79 | 2022-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $161.07 | 2023-2025 | Dupixent |
| Evoke Pharma, INC. | $154.86 | 2023 | Gimoti |
| Ironwood Pharmaceuticals, INC | $138.98 | 2021-2023 | Linzess |
| Mallinckrodt Hospital Products INC. | $121.83 | 2023 | Terlivaz |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $119.90 | 2022 | |
| Ardelyx, INC. | $106.31 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $81.17 | 2024-2025 | Zenpep |
| Gilead Sciences, INC. | $79.98 | 2021-2023 | |
| Nestle Healthcare Nutrition INC. | $74.83 | 2021-2023 | |
| Madrigal Pharmaceuticals | $69.54 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $62.97 | 2019-2023 | Rebyota |
| Celltrion USA INC. | $62.54 | 2025 | Vegzelma |
| Ethicon US, LLC | $61.03 | 2021 | |
| Daiichi Sankyo INC. | $55.66 | 2021-2022 | |
| Braintree Laboratories, INC. | $54.31 | 2023-2025 | Suflave |
| Organon LLC | $44.15 | 2023-2025 | Hadlima, Renflexis |
| Phathom Pharmaceuticals, INC. | $40.99 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $30.25 | 2023 | Dificid |
| Fresenius Kabi USA, LLC | $23.52 | 2023 | |
| Mylan Institutional INC. | $18.17 | 2023 | Hulio |
| Lilly USA, LLC | $17.84 | 2024 | Omvoh |
| Laborie Medical Technologies Corp. | $17.59 | 2024 | Solar Uroflow System |
| Alnylam Pharmaceuticals INC. | $15.47 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.